Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.

In Immunology SGI focus on three key areas; Rheumatology, Dermatology and Gastroenterology, aiming to provide insight and answer critical questions such as….Which are the more dynamic brands across key auto-immune indications and why? How quickly are immune specialists adopting newly approved and novel treatments? What hopes and aspirations do prescribers have for novel MOAs? How do new approvals challenge the current treatment algorithm? How do perception of manufacturers and brand promotional activity influence prescribing behavior?


How will the second generation IL-6 and JAK inhibitors in the pipeline impact the RA biologic market? Are rheumatologists becoming more comfortable prescribing Xeljanz for their RA patients and how is managed care impeding its use? How are rheumatologists preparing for the impending launch and introduction of biosimilars, specifically Inflectra, already FDA approved?

How is the adoption of Taltz affecting the PsO treatment algorithm?  How are dermatologists differentiating the various IL-17 inhibitors either already approved or pending FDA approval?  Where does Otezla fit in the PsO treatment algorithm?

How is the adoption of Entyvio affecting the IBD treatment algorithms for Crohn’s and UC? How do gastroenterologists perceive the various biologics/small molecules, including Xeljanz and Stelara, in development and how do they anticipate introducing them into their IBD armamentarium?

Direct from our Research!

Rheumatologists report significantly higher satisfaction with Cosentyx compared to Janssen’s Stelara with 46% stating the Cosentyx holds an efficacy advantage over Stelara.

Gastroenterologists identify the launch of Janssen’s Stelara as the most exciting thing to happen in IBD in 2016.

Among the pipeline agents for IBD, gastroenterologists are most familiar with Pfizer’s Xeljanz, an oral JAK-inhibitor already approved for rheumatoid arthritis.  Oral agents hold massive appeal in the IBD market with up to one-third of the gastroenterologists willing to accept lower efficacy for the convenience of a pill.

Entyvio has developed a solid user base since launch.73% of gastroenterologists are using Entyvio in ten or more of their patients, a number equal to Remicade. This increasing depth of use should lead to increase for the brand in the 25% or more of patients moving forward.

In rheumatoid arthritis, with the introduction of sarilumab, a new IL-6 that will go head-to-head with Roche’s Actemra and Olumiant (the second JAK to hit the market) the alternative MOA market is likely to expand.

Reports new KS-01

Quarterly survey of high dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions.

RealTime Dynamix: Rheumatoid Arthritis US 2017 (quarterly)
RealTime Dynamix: Psoriasis US 2017 (quarterly)
RealTime Dynamix: Ulcerative Colitis US 2017 (quarterly)
RealTime Dynamix: Crohn’s Disease US 2017 (quarterly)
RealTime Dynamix: Psoriatic Arthritis US 2017 (quarterly)
RealTime Dynamix: Atopic Dermatitis US 2017 (quarterly)
RealTime Dynamix: Ankylosing Spondylitis US 2017 (bi-annual)
RealTime Dynamix: IBS US 2017 (bi-annual)
RealTime Dynamix: Rheumatoid Arthritis EU 2017 (bi-annual)
RealTime Dynamix: Psoriatic Arthritis EU 2017 (bi-annual)
RealTime Dynamix: Rheumatology NP/PA 2017 (annual)


Market Dynmix

A forward looking report to anticipate how emerging treatments will influence future practice.

Market Dynamix: Gout US 2017
Market Dynamix: Osteoarthritis US 2017
Market Dynamix: Vasculitis US 2017
Market Dynamix: Lupus, Lupus Nephritis US 2017


Reports new KS-02

In-depth analysis of a robust sample of patient journeys detailing the realities of current practice.

RealWorld Dynamix: Biologic/JAK Switching in RA US 2017
RealWorld Dynamix: Biologic/JAK Switching in RA EU 2017
RealWorld Dynamix: Biologic/Otezla Switching in PsA US 2017
RealWorld Dynamix: Biologic/Otezla Switching in PsA EU 2017
RealWorld Dynamix: Biologic Switching IBD US 2017
RealWorld Dynamix: Biologic/Otezla Use in Psoriasis US 2017
RealWorld Dynamix: Biologic/Small Molecule Use in AS and non-radiographic SpA 2017


Reports new KS-02

A profile of the next generation of specialists and how they practice medicine.

Fellowship Dynamix: Rheumatology US 2017
Fellowship Dynamix: Dermatology US 2017
Fellowship Dynamix: Gastroenterology US 2017


Reports new KS-02

Profiling the business dynamics at the practice level and the impact of drug utilization.

Practice Dynamix: Rheumatology/Gastroenterology/Dermatology 2017